Author:
Braun G. S.,Kirschner M.,Rübben A.,Wahl R. U.,Amann K.,Benesova K.,Leipe J.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Kähler KC, Hassel JC, Heinzerling L et al (2016) Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom. J Dtsch Dermatol Ges 14:662–683
2. Heinzerling L, de Toni EN, Schett G et al (2019) Checkpoint inhibitors. Dtsch Arztebl Int 116:119–126
3. Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853–1862
4. Kim ST, Suarez-Almazor ME (2019) Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. Expert Rev Clin Immunol 15:211–213
5. Hassel JC, Heinzerling L, Aberle J et al (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36–49
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献